✨ Free AI Report
Apogee Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Apogee Therapeutics, Inc.
Company Research

Apogee Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Apogee Therapeutics, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Differentiated I&I biologics pipeline with extended half-life optimization, near-term Phase 3 catalyst, and runway to inflection points. The company operates within the healthcare sector, specifically in the biotechnology industry, with a market capitalization of approximately $4.78 billion. The company achieved positive results in the APEX Phase 2 Part A.

What is Apogee Therapeutics, Inc.'s industry? Apogee Therapeutics, Inc. (apogeetherapeutics.com) operates in Biotechnology - Immunology and Inflammatory Disease Therapeutics. AskCyborg classifies Apogee Therapeutics, Inc. under Biotechnology - Immunology and Inflammatory Disease Therapeutics in its company registry.

Apogee Therapeutics is a clinical stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory...

7/ 10Strong

Cyborg Score thesis

Differentiated I&I biologics pipeline with extended half-life optimization, near-term Phase 3 catalyst, and runway to inflection...

Read the full analyst-debate transcript →
Industry Biotechnology - Immunology and Inflammatory Disease Therapeutics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Apogee Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Apogee Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Apogee Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Apogee Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Apogee Therapeutics, Inc. Overview

Pro stress-test →

Apogee Therapeutics is a clinical stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immune (I&I) diseases with high unmet need. The company employs advanced antibody engineering to optimize drug half-life and durability, positioning itself to compete in large, underserved I&I markets.

Strategic Profile

Pro stress-test →

Apogee's antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Apogee's financial strength is underscored by a robust balance sheet and sufficient funding through 2028.

Competitive Landscape

Pro stress-test →

The company is strategically positioned in the biotechnology sector, focusing on immunology and inflammation. Apogee competes in I&I biologics against established players with approved therapies (e.g., Dupilumab/DUPIXENT) and emerging clinical-stage competitors. Differentiation hinges on extended half-life engineering, combination therapy potential, and dosing advantages.

Industry Context

Apogee Therapeutics, Inc. operates in Biotechnology - Immunology and Inflammatory Disease Therapeutics.

Key facts

Headquarters: San Francisco, US · Market cap: $3.68B - $4.78B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Apogee Therapeutics, Inc..

  • Zumilokibart (APG777), the company's most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets, as well as asthma
  • In the latter half of 2026, a head-to-head comparison of APG279 against DUPIXENT is expected to deliver the first proof-of-concept for Apogee's combination therapies in AD
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2026Critical 52-week maintenance readout from APEX Phase 2 Part A for zumilokibart in atopic dermatitis expected
  • Q2 2026Phase 2 Part B dose optimization readout expected; Phase 3 initiation targeted by end of 2026
  • +1 moreTrack every material event for Apogee Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Apogee Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

DupilumabIL-4Rα antagonist for atopic dermatitis; market-leading standard of care→TralokinumabIL-13 antagonist for moderate-to-severe atopic dermatitis→GSK respiratory/immunology pipelineMultiple I&I programs in asthma, COPD, and dermatology→

Compare Apogee Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Apogee Therapeutics, Inc. operates in Biotechnology - Immunology and Inflammatory Disease Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Immunology and Inflammatory Disease Therapeutics research →
NEW · MCP server

Ask your AI assistant about Apogee Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Apogee Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Apogee Therapeutics, Inc. do this quarter?”
“Is Apogee Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Apogee Therapeutics, Inc. do?+
Apogee Therapeutics is a clinical stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory...
What is Apogee Therapeutics, Inc.'s Cyborg Score?+
Apogee Therapeutics, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Apogee Therapeutics, Inc.'s main competitors?+
Named competitors include Dupilumab, Tralokinumab, GSK respiratory/immunology pipeline. The full competitive landscape is in the AskCyborg report.
How can I get the full Apogee Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Apogee Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Apogee Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.